Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Fri, 17 May 2024 04:00:00 GMT In the recent past, there have been concerns over DexCom’s growth potential, given the success of Novo Nordisk and Eli Lilly with their ... DexCom in its recent press release stated that while the new ...
Thu, 16 May 2024 07:47:00 GMT A fire broke out Thursday on the roof of a new building under construction at a Novo Nordisk manufacturing site in Kalundborg, Denmark, where the drug maker is expanding capacity for its popular ...
Thu, 16 May 2024 07:08:00 GMT The results, from a small trial of a drug called CT-388, hint that Roche could be a serious player in the weight-loss market in coming years.
Thu, 02 May 2024 05:00:00 GMT Alkermes and Novo Nordisk also entered into subcontracting ... Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private ...
Mon, 29 Apr 2024 08:00:00 GMT Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $97.5 to $150.0 for Novo Nordisk ... earnings release is in 3 days.
